Abstract | BACKGROUND: OBJECTIVES: METHODS: RESULTS: Eight patients in the betamethasone group were considered as cured, two as improved and four as nonresponders at the end of the treatment period. Thirteen patients in the tacrolimus group were considered as cured and one as improved at the end of the treatment period. Nine patients in the emollient group were considered as stable and six failed to respond. Both betamethasone and tacrolimus groups presented statistically significantly greater cure or improvement rates when compared with the emollient group (P<0.001). CONCLUSIONS:
|
Authors | D Rigopoulos, S Gregoriou, E Belyayeva, G Larios, G Kontochristopoulos, A Katsambas |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 160
Issue 4
Pg. 858-60
(Apr 2009)
ISSN: 1365-2133 [Electronic] England |
PMID | 19120329
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Immunosuppressive Agents
- Ointments
- Betamethasone Valerate
- Tacrolimus
|
Topics |
- Betamethasone Valerate
(adverse effects, therapeutic use)
- Candidiasis
(drug therapy)
- Chronic Disease
- Female
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Ointments
- Paronychia
(drug therapy)
- Tacrolimus
(adverse effects, therapeutic use)
- Treatment Outcome
|